Observational cohort of patients with liver cancer
Cohort Study of Patients With Primary Hepatocellular Carcinoma or Cholangiocarcinoma
This study is tracking patients with aggressive liver cancers to see how their treatment and outcomes change over time, hoping to improve their care and find better treatment options.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 1250 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Assistance Publique - Hôpitaux de Paris Academic / other |
| Locations | 1 site (Paris) |
| Trial ID | NCT04340986 on ClinicalTrials.gov |
What this trial studies
This study aims to collect and analyze data from patients diagnosed with hepatocellular carcinoma or cholangiocarcinoma, both of which are aggressive liver cancers. By tracking the evolution of these patients over time, the study seeks to enhance understanding of their care, improve diagnostic and prognostic methods, and identify new therapeutic targets. The research focuses on patients who have been receiving medical care in the nephrology department since 2015, ensuring a comprehensive follow-up of their treatment and outcomes.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 and older with histologically or cytologically documented cholangiocarcinoma or hepatocellular carcinoma.
Not a fit: Patients who do not have a documented diagnosis of cholangiocarcinoma or hepatocellular carcinoma, or those who oppose participation, may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved personalized treatment strategies and better management of liver cancer patients.
How similar studies have performed: While this approach is observational and builds on existing knowledge, similar studies have shown promise in improving patient outcomes in cancer care.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: Inclusion Criteria : * Age ≥ 18 years olds * Medical care in Nephrology department since 2015 Cholangiocarcinoma: \- Histologically and cytologically documented cholangiocarcinoma, regardless of the stage of the disease Hepatocellular carcinoma: * Hepatocellular carcinoma at any stage of the disease, presenting the diagnostic criteria according to the diagnostic criteria of Barcelona : Tumor of more than 1 cm, developed on cirrhosis liver with arterial phase hyperenhancement and washout in the portal venous or delayed phases on CT and MRI * Hepatocellular histologically documented Exclusion Criteria: \- Lack of patient non-opposition
Where this trial is running
Paris
- Serviec hépatologie-Hôpital Saint Antoine — Paris, France (Recruiting)
Study contacts
- Principal investigator: Marie LEQUOY, MD — AssistancePublique-Hôpitaux de Paris
- Study coordinator: Marie LEQUOY, MD
- Email: marie.lequoy@aphp.fr
- Phone: +330149283154
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.